Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clonidine Does Not Potentiate the Antipsychotic Effects of Neuroleptics in Chronically Ill Patients

Clonidine Does Not Potentiate the Antipsychotic Effects of Neuroleptics in Chronically Ill Patients Clonidine is a centrally acting antihypertensive and has been prescribed widely for more than 20 years. Because it decreases central norepinephrine activity, clonidine has been investigated as an antipsychotic. In most of the preliminary studies, clonidine was tested as the sole antipsychotic agent. We performed a double-blind, placebo-controlled, crossover study to compare a placebo plus a neuroleptic to clonidine plus a neuroleptic in a group of 16 chronically psychotic patients. Of these 16, 3 dropped out secondary to side effects of the clonidine and 1 withdrew from the study. The clonidine dosage varied from 0.2 to 0.6 mg per day. The concurrent neuroleptic (one of the following: haloperidol, thiothixene, thioridazine, mesoridazine, or fluphenazine) averaged 34 mg per day of haloperidol equivalents. Symptoms were monitored using the Psychiatric Symptoms Assessment Scale. The data provided evidence that a clonidine/neuroleptic combination was not more effective than a neuroleptic alone in this group of patients. These data suggest that the central antino-repinephrine activity of a neuroleptic is not potentiated further by clonidine. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Clonidine Does Not Potentiate the Antipsychotic Effects of Neuroleptics in Chronically Ill Patients

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/clonidine-does-not-potentiate-the-antipsychotic-effects-of-i0m50PSEtp
Publisher
Springer Journals
Copyright
Copyright © 1998 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1026194411452
Publisher site
See Article on Publisher Site

Abstract

Clonidine is a centrally acting antihypertensive and has been prescribed widely for more than 20 years. Because it decreases central norepinephrine activity, clonidine has been investigated as an antipsychotic. In most of the preliminary studies, clonidine was tested as the sole antipsychotic agent. We performed a double-blind, placebo-controlled, crossover study to compare a placebo plus a neuroleptic to clonidine plus a neuroleptic in a group of 16 chronically psychotic patients. Of these 16, 3 dropped out secondary to side effects of the clonidine and 1 withdrew from the study. The clonidine dosage varied from 0.2 to 0.6 mg per day. The concurrent neuroleptic (one of the following: haloperidol, thiothixene, thioridazine, mesoridazine, or fluphenazine) averaged 34 mg per day of haloperidol equivalents. Symptoms were monitored using the Psychiatric Symptoms Assessment Scale. The data provided evidence that a clonidine/neuroleptic combination was not more effective than a neuroleptic alone in this group of patients. These data suggest that the central antino-repinephrine activity of a neuroleptic is not potentiated further by clonidine.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 13, 2004

References

  • Drugs five years later: Clonidine
    Lowenstein, J
  • Sixth Gaddum Lecture: National Institute for Medical Research, Mill Hill, Jan 1977. Presynaptic receptors and their role in the regulation of transmitter release
    Langer, SZ
  • Partial agonist of clonidinc on prejunctional and postjunctional alpha adrenoceptor
    Medgett, IC; McCulloch, MW; Rand, MJ
  • Effect of some antiarrhythmics on [3H]clonidine binding to alpha 2 adrenergic receptors
    Ciofalo, JR
  • Norepinephrine in chronic paranoid schizophrenia: Above normal levels in limbic forebrain
    Farley, JJ; Price, KS; McCullogh, E; Deck, JHN; Hordynski, W; Hornykiewicz, O
  • Noradrenergic overactivity in chronic schizophrenia: Evidence based on cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations
    Gomes, UCR; Stanley, BC; Potgieter, L; Roux, JT
  • Schizophrenia: Elevated cerebrospinal fluid norepinephrine
    Lake, CR; Sternberg, DE; van Kammen, DP; Ballenger, JC; Ziegler, MG; Post, RM; Kopin, IJ; Bunney, WE
  • Brain catecholamines in schizophrenia: A good case for noradrenaline
    Hornykiewicz, O
  • CSF monoamine metabolites in mania
    Swann, AC; Secunda, S; Davis, JM; Robins, E; Hanin, I; Koslow, SH; Maas, JW
  • Cerbrospinal fluid amine metabolites: Relationship with behavioral measurements in depressed, manic, and healthy control subjects
    Redmond, DE; Katz, MM; Maas, JW; Swann, A; Casper, R; Davis, JM
  • A preliminary evaluation of the sedative effects of Catapres, a new antihypertensive agent, in chronic schizophrenic patients
    Simpson, GM; Kunz-Bartholini, E; Watts, TPS
  • A pilot study of ST-155 (Catapres) in chronic schizophrenics
    Sugarman, AA
  • Clonidine treatment of schizophrenics: Can we predict treatment response?
    van Kammen, DP; Peters, JL; van Kammen, WB
  • Preliminary studies of clonidine in psychotic patients
    Angrist, B; Smith, M; Adler, L
  • Clonidine treatment of schizophrenia: Double-blind comparison to placebo and neuroleptic drugs
    Freedman, R; Kirch, D; Bell, L
  • The use of clonidine in psychiatry
    El-Mallakh, RS
  • Efficacy of clonidine in 24 patients with acute mania
    Hardy, MC; Lecrubier, Y; Widlöcher, D
  • Clonidine in mania
    Glannini, AJ; Extein, I; Gold, MS
  • Diagnostic and Statistical Manual III, Revised
  • Structured Clinical Interview for DSM-III-R
  • The Psychiatric Symptom Assessment Scale (PSAS)
    Bigelow, L; Bryan, D
  • The Brief Psychiatric Rating Scale
    Overall, JE; Gorham, DR
  • Statistical Power Analysis for Behavior Science
    Cohen, J
  • Contemporary Directions in Psychopathology
    Karson, CN; Kleinman, JE; Wyatt, RT
  • α-Adrenergic receptor function in schizophrenia
    Kafka, MS; van Kammen, DP
  • Receptors for Neurotransmitters and Peptide Hormones
    Farley, IJ; Sharnak, KS; Hornykiewicz, O
  • Comprehensive Textbook of Psychiatry/V
    Kaplan, HI; Sadock, BJ
  • Catecholamines: Basic and Clinical Frontiers
    Kleinman, JE; Bridge, TP; Karoum, F; Speciale, S; Staub, R; Zalcman, S; Gillin, JC; Wyatt, RJ
  • Psychopharmacology: The Fourth Generation of Progress
    Charney, DS; Bremner, D; Redmund, DE
  • Aggressive behavior induced by large doses of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST-155) in mice
    Morpurgo, C